Susan J. Little
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan J. Little has a total of 449 co-authors. Here are the top co-authors by number of shared publications:
- Sanjay R. Mehta
Division of Infectious Diseases and Global Public Health, University of California San Diego, CA, USA
7 shared publications - Angela R. Branche
Vaccine and Treatment Evaluation Unit, University of Rochester, Rochester, USA
4 shared publications - Angelica Cifuentes Kottkamp
Vaccine and Treatment Evaluation Unit, Manhattan Research Clinic, New York University Grossman School of Medicine, New York, USA
4 shared publications - Antoine Chaillon
Department of Medicine, University of California, San Diego, CA 92093, USA
4 shared publications - Craig A. Magaret
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
4 shared publications - Dahlene N. Fusco
Department of Medicine, Tulane University School of Medicine, New Orleans, USA
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Distinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDistinct T cell correlates of COVID-19 risk before and after a second booster in previously SARS-CoV-2 infected versus naïve COVAIL trial participants
- Open Access
- 17 April 2026
- Published by Elsevier in SSRN Electronic Journal
Incident HIV Infection and Cumulative Viral Load Drive Community HIV Cluster Growth
Background: Molecular HIV surveillance (MHS) is routinely used by public health departments to monitor HIV transmission dynamics and identify rapidly growing transmission clusters (groups of one or more genetically linked individuals) for targeted prevention and response. Current approaches to assessing cluster growth typically rely on fixed-window metrics, such as counts of new diagnoses over 12 months, and do not capture the continuous evolution of clusters or time-varying clinical and demographic factors. These limitations reduce the ability of surveillance systems to prioritize cluster response on the basis of key epidemic drivers, such as incident infection or viral load, that may be associated with future cluster growth.Methods: We analyzed de-identified HIV surveillance data, including partial pol sequences from routine drug-resistance genotyping, from San Diego County (SDC) (2017–2020; N = 1,241 cases forming 1,118 clusters, including singletons, by the end of 2020) and Miami-Dade County (MDC) (2017–2022; N = 3,448 cases forming 2,972 clusters by the end of 2022). Molecular clusters were defined using a ≤0.5% pairwise genetic-distance threshold. Incident cluster growth was modeled with an Andersen-Gill recurrent event model incorporating time-varying individual-level and cluster-level covariates; model estimates were used for counterfactual prediction.Findings: Most clusters remained singletons (single-individual clusters with no subsequent genetically linked cases) throughout follow-up (93.5% in SD; 92.9% in MD). Among growing clusters, only a subset showed incident or mixed growth (2.2% of clusters in SD; 2.9% in MD) with at least one incident infection during follow-up, indicating ongoing transmission during the surveillance period. In both jurisdictions, a higher proportion of incident infections and greater cumulative log viral load burden were associated with faster incident cluster growth. In SD, a 10-percentage-point increase in the proportion of incident infections was associated with a 53% higher incident cluster growth rate (hazard ratio [HR], 1.53; 95% CI, 1.43–1.62); in MD, the corresponding increase was 30% (HR, 1.30; 95% CI, 1.26–1.34). Counterfactual analyses showed that sustained reductions in incident infections and cumulative viral load substantially attenuated predicted incident cluster growth. Reducing the proportion of incident infections from 10% to 1% corresponded to approximately 61 fewer linked cases in SD over four years and 103 fewer in MD over the six years following identification of the incident case. A scenario that reduced cumulative log viral load burden from 3.9 to 1.3 corresponded to approximately 96 fewer cases in SD and 521 fewer in MD over the same 4-year and 6-year period, respectively. By contrast, counterfactual reductions in bacterial sexually transmitted infection prevalence produced comparatively modest effects.Interpretation: Using routinely collected HIV surveillance data, a recurrent event framework quantified how incident infection and viral load shape the pace of HIV cluster growth over time and enabled counterfactual evaluation of plausible intervention scenarios. This approach may strengthen the ability of health departments to prioritize timely interventions to reduce onward transmission.
- 17 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIncident HIV Infection and Cumulative Viral Load Drive Community HIV Cluster Growth
Background: Molecular HIV surveillance (MHS) is routinely used by public health departments to monitor HIV transmission dynamics and identify rapidly growing transmission clusters (groups of one or more genetically linked individuals) for targeted prevention and response. Current approaches to assessing cluster growth typically rely on fixed-window metrics, such as counts of new diagnoses over 12 months, and do not capture the continuous evolution of clusters or time-varying clinical and demographic factors. These limitations reduce the ability of surveillance systems to prioritize cluster response on the basis of key epidemic drivers, such as incident infection or viral load, that may be associated with future cluster growth.Methods: We analyzed de-identified HIV surveillance data, including partial pol sequences from routine drug-resistance genotyping, from San Diego County (SDC) (2017–2020; N = 1,241 cases forming 1,118 clusters, including singletons, by the end of 2020) and Miami-Dade County (MDC) (2017–2022; N = 3,448 cases forming 2,972 clusters by the end of 2022). Molecular clusters were defined using a ≤0.5% pairwise genetic-distance threshold. Incident cluster growth was modeled with an Andersen-Gill recurrent event model incorporating time-varying individual-level and cluster-level covariates; model estimates were used for counterfactual prediction.Findings: Most clusters remained singletons (single-individual clusters with no subsequent genetically linked cases) throughout follow-up (93.5% in SD; 92.9% in MD). Among growing clusters, only a subset showed incident or mixed growth (2.2% of clusters in SD; 2.9% in MD) with at least one incident infection during follow-up, indicating ongoing transmission during the surveillance period. In both jurisdictions, a higher proportion of incident infections and greater cumulative log viral load burden were associated with faster incident cluster growth. In SD, a 10-percentage-point increase in the proportion of incident infections was associated with a 53% higher incident cluster growth rate (hazard ratio [HR], 1.53; 95% CI, 1.43–1.62); in MD, the corresponding increase was 30% (HR, 1.30; 95% CI, 1.26–1.34). Counterfactual analyses showed that sustained reductions in incident infections and cumulative viral load substantially attenuated predicted incident cluster growth. Reducing the proportion of incident infections from 10% to 1% corresponded to approximately 61 fewer linked cases in SD over four years and 103 fewer in MD over the six years following identification of the incident case. A scenario that reduced cumulative log viral load burden from 3.9 to 1.3 corresponded to approximately 96 fewer cases in SD and 521 fewer in MD over the same 4-year and 6-year period, respectively. By contrast, counterfactual reductions in bacterial sexually transmitted infection prevalence produced comparatively modest effects.Interpretation: Using routinely collected HIV surveillance data, a recurrent event framework quantified how incident infection and viral load shape the pace of HIV cluster growth over time and enabled counterfactual evaluation of plausible intervention scenarios. This approach may strengthen the ability of health departments to prioritize timely interventions to reduce onward transmission.
- Open Access
Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US
Machine learning (ML) algorithms may be effective at improving the HCV care cascade. One ML algorithm, developed using U.S. ambulatory electronic medical records (EMR), demonstrated the ability to identify people infected with HCV earlier than conventional testing strategies among those with indications for screening. We evaluated the potential cost-effectiveness of ML-enabled screening for the early identification of undiagnosed HCV among people in care in the U.S. An HCV natural history Markov model was developed to evaluate the cost-effectiveness of the ML algorithm-enabled screening compared to conventional testing over the training data period. Based on the training data, the ML algorithm identified patients on average 6.5 months earlier than conventional testing strategies. We compared the status quo to intervention scenarios using the ML algorithm at different recall levels (proportion of HCV patients identified, 5–100%). We identified the optimal algorithm recall level, which maximized health (measured in quality-adjusted life years, QALYs) while staying under a willingness-to-pay threshold of USD$100,000/QALY gained. ML-enabled screening was cost-effective (ICER < $100 k/QALY gained) in identifying undiagnosed HCV patients for recall levels up to 30%. The optimal recall level was 30% (Precision 0.27%), which resulted in a mean ICER of $94,022/QALY gained. ML-enabled screening for the early identification of undiagnosed HCV patients could be cost-effective in the U.S. Prospective evaluation of real-world effectiveness is warranted.
Open AccessPotential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US
Machine learning (ML) algorithms may be effective at improving the HCV care cascade. One ML algorithm, developed using U.S. ambulatory electronic medical records (EMR), demonstrated the ability to identify people infected with HCV earlier than conventional testing strategies among those with indications for screening. We evaluated the potential cost-effectiveness of ML-enabled screening for the early identification of undiagnosed HCV among people in care in the U.S. An HCV natural history Markov model was developed to evaluate the cost-effectiveness of the ML algorithm-enabled screening compared to conventional testing over the training data period. Based on the training data, the ML algorithm identified patients on average 6.5 months earlier than conventional testing strategies. We compared the status quo to intervention scenarios using the ML algorithm at different recall levels (proportion of HCV patients identified, 5–100%). We identified the optimal algorithm recall level, which maximized health (measured in quality-adjusted life years, QALYs) while staying under a willingness-to-pay threshold of USD$100,000/QALY gained. ML-enabled screening was cost-effective (ICER < $100 k/QALY gained) in identifying undiagnosed HCV patients for recall levels up to 30%. The optimal recall level was 30% (Precision 0.27%), which resulted in a mean ICER of $94,022/QALY gained. ML-enabled screening for the early identification of undiagnosed HCV patients could be cost-effective in the U.S. Prospective evaluation of real-world effectiveness is warranted.
- Open Access
- 14 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1)
More evidence is needed to improve molecular HIV surveillance for cluster detection and response
Background: Molecular HIV surveillance (MHS) is used in the U.S. to inform public health prevention and intervention activities aimed at helping end the HIV epidemic. Its application in this context is currently challenged by ethical, legal, and social concerns, with gaps in understanding how end users weigh these issues. We sought to identify the preferences of MHS end users for improving MHS. Methods: End users completed 12 choice experiment tasks evaluating five attributes of MHS for cluster detection and response. We generated a choice model using conditional logit and report results as relative attribute importance scores, comparing them to attitudinal data from close-ended questions. Responses to open-ended questions provide additional context on areas for MHS improvement. Results: We report findings from 55 of 90 potential end-users who felt capable and agreed to participate. End users include researchers (n = 28) and public health practitioners (n = 27); their preferences do not differ significantly (p = 0.174) so their responses are combined. The highest weight is placed on certainty of MHS benefit (38%), followed by depth of HIV sequence sampling (26%). Lower weight is given to reducing stigma (20%) and personalized inferences (10%) and communication (6%). End users highlight improving MHS through implementation support, community engagement, transparent communication, intervention assistance, risk minimization, and impact assessment; researchers stress the need for better data access. Conclusions: End users place the highest value on having more evidence of MHS benefits. Improving MHS requires attention to implementation support, community engagement, transparent communication, intervention assistance, risk mitigation, impact assessment, and data access.
- 14 November 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1)
Open AccessMore evidence is needed to improve molecular HIV surveillance for cluster detection and response
Background: Molecular HIV surveillance (MHS) is used in the U.S. to inform public health prevention and intervention activities aimed at helping end the HIV epidemic. Its application in this context is currently challenged by ethical, legal, and social concerns, with gaps in understanding how end users weigh these issues. We sought to identify the preferences of MHS end users for improving MHS. Methods: End users completed 12 choice experiment tasks evaluating five attributes of MHS for cluster detection and response. We generated a choice model using conditional logit and report results as relative attribute importance scores, comparing them to attitudinal data from close-ended questions. Responses to open-ended questions provide additional context on areas for MHS improvement. Results: We report findings from 55 of 90 potential end-users who felt capable and agreed to participate. End users include researchers (n = 28) and public health practitioners (n = 27); their preferences do not differ significantly (p = 0.174) so their responses are combined. The highest weight is placed on certainty of MHS benefit (38%), followed by depth of HIV sequence sampling (26%). Lower weight is given to reducing stigma (20%) and personalized inferences (10%) and communication (6%). End users highlight improving MHS through implementation support, community engagement, transparent communication, intervention assistance, risk minimization, and impact assessment; researchers stress the need for better data access. Conclusions: End users place the highest value on having more evidence of MHS benefits. Improving MHS requires attention to implementation support, community engagement, transparent communication, intervention assistance, risk mitigation, impact assessment, and data access.
- 1 September 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 100 (1) , e1
Clinician Perspectives on Disclosing Public Health Uses of HIV Antiretroviral Resistance Testing Results
An abstract is unavailable. This article is available as a PDF only.
- 1 September 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 100 (1) , e1
Clinician Perspectives on Disclosing Public Health Uses of HIV Antiretroviral Resistance Testing Results
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (4) , 325-333
Predictive Models to Identify Individuals With HIV at Risk of Unsuppressed Viral Load Using Routine Public Health Data
Background: Effective antiretroviral therapy to maintain durable viral suppression is key to ending the HIV epidemic in the United States. We evaluated the ability of machine learning algorithms to predict people with HIV (PWH) at risk of unsuppressed viral load. Setting: Retrospective study among PWH from San Diego County (n = 18,916). The study used reported public health HIV data (2017–2022) to predict the outcome of HIV viral load >200 copies/mL during a year-long prediction window. Methods: The data was partitioned by calendar date into two training and one validation datasets to accurately assess performance for predicting future observations. A random forest model was used to generate outcome predictions for the overall population and stratified by race. Mediation analysis was undertaken to assess underlying causality. Results: The model had an area under the receiver operating characteristic curve of 82.2 (95% CI: 79.3 to 85.0), a sensitivity of 33.8% (95% CI: 28.6 to 39.0), and specificity of 96.9% (95% CI: 95.7 to 97.2) corresponding to a positive predictive value of 55.7% (95% CI: 48.7 to 62.8) and negative predictive value of 91.7% (95% CI: 90.6 to 92.8). The area under the receiver operating characteristic was similar across races. Prior viral load characteristics were identified as the most important variables; however, they partially acted as mediators of underlying demographic (eg, race) and HIV infection risk (eg, injection drug use). Conclusions: Machine learning algorithms using mandatory reported public health HIV data can predict which PWH will have future unsuppressed viral load. Future work will assess its clinical utility compared to existing data-to-care initiatives.
- 1 August 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 99 (4) , 325-333
Open AccessPredictive Models to Identify Individuals With HIV at Risk of Unsuppressed Viral Load Using Routine Public Health Data
Background: Effective antiretroviral therapy to maintain durable viral suppression is key to ending the HIV epidemic in the United States. We evaluated the ability of machine learning algorithms to predict people with HIV (PWH) at risk of unsuppressed viral load. Setting: Retrospective study among PWH from San Diego County (n = 18,916). The study used reported public health HIV data (2017–2022) to predict the outcome of HIV viral load >200 copies/mL during a year-long prediction window. Methods: The data was partitioned by calendar date into two training and one validation datasets to accurately assess performance for predicting future observations. A random forest model was used to generate outcome predictions for the overall population and stratified by race. Mediation analysis was undertaken to assess underlying causality. Results: The model had an area under the receiver operating characteristic curve of 82.2 (95% CI: 79.3 to 85.0), a sensitivity of 33.8% (95% CI: 28.6 to 39.0), and specificity of 96.9% (95% CI: 95.7 to 97.2) corresponding to a positive predictive value of 55.7% (95% CI: 48.7 to 62.8) and negative predictive value of 91.7% (95% CI: 90.6 to 92.8). The area under the receiver operating characteristic was similar across races. Prior viral load characteristics were identified as the most important variables; however, they partially acted as mediators of underlying demographic (eg, race) and HIV infection risk (eg, injection drug use). Conclusions: Machine learning algorithms using mandatory reported public health HIV data can predict which PWH will have future unsuppressed viral load. Future work will assess its clinical utility compared to existing data-to-care initiatives.
- Open Access
- 11 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8)
Individual- and Neighborhood-Level Predictors of HIV Care Continuum Progression: Clark County, Nevada
Background: As the US human immunodeficiency virus (HIV) epidemic is disproportionately affecting underserved communities, it is critically important to investigate how social determinants of health affect diagnosis, treatment, and prevention of HIV infection and access to care. This article presents an investigation of the HIV epidemic in Clark County, Nevada, to identify local predictors of progression along the HIV care continuum. Methods: Deidentified HIV surveillance data from 2011 to 2022 were analyzed. We investigated associations between stages of care and individual-level demographics and zip code–level characteristics using (1) generalized linear mixed-effects models for univariate analysis, (2) penalized generalized linear mixed-effects models to simultaneously conduct variable selection and estimation for multivariate analysis, and (3) geospatial analysis. Results: Individual-level factors (diagnosis year, age at diagnosis, being Hispanic, being a man who has sex with men, sex at birth, and individual-level membership in a genetic cluster) and zip code–level factors (genetic clustering and social determinants of health, including level of poverty, proportion Hispanic, proportion with high school education, proportion white, and employment status) were associated with progression through the care continuum. A key result from our multivariate analysis is higher-poverty areas are associated with lower rates of persons with HIV in care (estimate [SE], −0.42 [0.17]; P = .02) and viral suppression (−0.48 [0.15]; P = .001). Conclusions: Our findings highlight the need for linking and engaging individuals in higher-poverty neighborhoods to medical providers. Furthermore, our results support the need for additional treatment adherence services in those same neighborhoods to increase viral suppression rates.
- 11 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8)
Open AccessIndividual- and Neighborhood-Level Predictors of HIV Care Continuum Progression: Clark County, Nevada
Background: As the US human immunodeficiency virus (HIV) epidemic is disproportionately affecting underserved communities, it is critically important to investigate how social determinants of health affect diagnosis, treatment, and prevention of HIV infection and access to care. This article presents an investigation of the HIV epidemic in Clark County, Nevada, to identify local predictors of progression along the HIV care continuum. Methods: Deidentified HIV surveillance data from 2011 to 2022 were analyzed. We investigated associations between stages of care and individual-level demographics and zip code–level characteristics using (1) generalized linear mixed-effects models for univariate analysis, (2) penalized generalized linear mixed-effects models to simultaneously conduct variable selection and estimation for multivariate analysis, and (3) geospatial analysis. Results: Individual-level factors (diagnosis year, age at diagnosis, being Hispanic, being a man who has sex with men, sex at birth, and individual-level membership in a genetic cluster) and zip code–level factors (genetic clustering and social determinants of health, including level of poverty, proportion Hispanic, proportion with high school education, proportion white, and employment status) were associated with progression through the care continuum. A key result from our multivariate analysis is higher-poverty areas are associated with lower rates of persons with HIV in care (estimate [SE], −0.42 [0.17]; P = .02) and viral suppression (−0.48 [0.15]; P = .001). Conclusions: Our findings highlight the need for linking and engaging individuals in higher-poverty neighborhoods to medical providers. Furthermore, our results support the need for additional treatment adherence services in those same neighborhoods to increase viral suppression rates.
- Open Access
- 17 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.4/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 (“COVID-19”) and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. Consistently across the Moderna and Pfizer-BioNTech vaccine platforms and across all variant Spike inserts assessed, both peak and exposure-proximal (“predicted-at-exposure”) titers correlated with lower Omicron COVID-19 risk in individuals previously infected with SARS-CoV-2, albeit significantly less so in naïve individuals [e.g., exposure-proximal hazard ratio per 10-fold increase in BA.1 titer 0.74 (95% CI 0.59, 0.94) for naïve vs. 0.41 (95% CI 0.23, 0.64) for non-naïve; interaction p = 0.013]. Neutralizing antibody titer was a strong inverse correlate of Omicron COVID-19 in non-naïve individuals and a weaker correlate in naïve individuals, posing questions about how prior infection alters the neutralization correlate.
- 17 January 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessNeutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.4/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 (“COVID-19”) and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. Consistently across the Moderna and Pfizer-BioNTech vaccine platforms and across all variant Spike inserts assessed, both peak and exposure-proximal (“predicted-at-exposure”) titers correlated with lower Omicron COVID-19 risk in individuals previously infected with SARS-CoV-2, albeit significantly less so in naïve individuals [e.g., exposure-proximal hazard ratio per 10-fold increase in BA.1 titer 0.74 (95% CI 0.59, 0.94) for naïve vs. 0.41 (95% CI 0.23, 0.64) for non-naïve; interaction p = 0.013]. Neutralizing antibody titer was a strong inverse correlate of Omicron COVID-19 in non-naïve individuals and a weaker correlate in naïve individuals, posing questions about how prior infection alters the neutralization correlate.
- 17 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (3) , 643-652
Phylodynamics for Human Immunodeficiency Virus Prevention: A Miami-Dade County Case Study
Background: To date, human immunodeficiency virus (HIV) molecular epidemiology has been primarily used to identify clusters of related infections (cluster detection and response) and then address interventions to these clusters. Community groups have raised concern regarding cluster detection and response related to privacy and ethical concerns. Here we demonstrate how an alternative approach to HIV molecular epidemiology can provide public health benefit. Methods: A limited data set for Miami-Dade County provided by the Florida Department of Health was curated and annotated by neighborhood health district (NBHD) and genetic linkage (using a genetic distance threshold of ≤0.5%) and phylodynamic analyses were performed. Phylodynamic analyses were used to infer viral transmissions into Miami-Dade County and between NBHDs within the county. Results: A total of 7274 HIV sequences from unique persons collected between 1 January 2015 and 31 December 2021 were analyzed, including 50% of the 7894 new diagnoses during this period. The proportion of sequences in local clusters increased over time. Higher ratios of local introductions, compared to viral egress (ie, source of local clusters in other NBHDs) were observed in 3 NBHDs in North Miami (range, 1.9–2.5), suggesting earlier diagnosis, but high numbers of susceptible persons not receiving preexposure prophylaxis. South Dade/Homestead had a low ratio (0.3) of local introductions compared with egress, suggesting later diagnosis and less durable suppression. Conclusions: Phylodynamic and genetic linkage analyses can highlight populations and geographic regions that might benefit more from particular types of HIV prevention interventions. These findings will need to be explored by evaluating the impact of scaling up interventions informed by these analyses.
- 17 December 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 231 (3) , 643-652
Phylodynamics for Human Immunodeficiency Virus Prevention: A Miami-Dade County Case Study
Background: To date, human immunodeficiency virus (HIV) molecular epidemiology has been primarily used to identify clusters of related infections (cluster detection and response) and then address interventions to these clusters. Community groups have raised concern regarding cluster detection and response related to privacy and ethical concerns. Here we demonstrate how an alternative approach to HIV molecular epidemiology can provide public health benefit. Methods: A limited data set for Miami-Dade County provided by the Florida Department of Health was curated and annotated by neighborhood health district (NBHD) and genetic linkage (using a genetic distance threshold of ≤0.5%) and phylodynamic analyses were performed. Phylodynamic analyses were used to infer viral transmissions into Miami-Dade County and between NBHDs within the county. Results: A total of 7274 HIV sequences from unique persons collected between 1 January 2015 and 31 December 2021 were analyzed, including 50% of the 7894 new diagnoses during this period. The proportion of sequences in local clusters increased over time. Higher ratios of local introductions, compared to viral egress (ie, source of local clusters in other NBHDs) were observed in 3 NBHDs in North Miami (range, 1.9–2.5), suggesting earlier diagnosis, but high numbers of susceptible persons not receiving preexposure prophylaxis. South Dade/Homestead had a low ratio (0.3) of local introductions compared with egress, suggesting later diagnosis and less durable suppression. Conclusions: Phylodynamic and genetic linkage analyses can highlight populations and geographic regions that might benefit more from particular types of HIV prevention interventions. These findings will need to be explored by evaluating the impact of scaling up interventions informed by these analyses.